Aegerion Pharmaceuticals Now Covered by Analysts at Bank of America (AEGR)
Equities researchers at Bank of America assumed coverage on shares of Aegerion Pharmaceuticals (NASDAQ: AEGR) in a report issued on Tuesday. The firm set a “buy” rating and a $39.00 price target on the stock.
Aegerion Pharmaceuticals opened at 32.52 on Tuesday. Aegerion Pharmaceuticals has a 1-year low of $11.75 and a 1-year high of $32.63. The stock’s 50-day moving average is currently $28.25. The company’s market cap is $828.5 million.
Several other analysts have also recently commented on the stock. Analysts at Lazard Capital Markets upgraded shares of Aegerion Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note to investors on Monday, February 11th. Separately, analysts at Deutsche Bank raised their price target on shares of Aegerion Pharmaceuticals from $30.00 to $37.00 in a research note to investors on Monday, January 28th. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Aegerion Pharmaceuticals from $30.00 to $35.00 in a research note to investors on Thursday, January 24th. They now have an “outperform” rating on the stock.
Aegerion Pharmaceuticals, Inc. (Aegerio) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.